Trial Profile
Safety and Therapeutic Efficacy of the Broadly Neutralizing HIV-1 Specific Monoclonal Antibody VRC01 During Analytic Treatment Interruption in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2022
Price :
$35
*
At a glance
- Drugs VRC 01 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 16 Feb 2022 Results from this study and other study assessing Impact of Treatment Interruption on Colonic Mucosa in Acutely Treated Participants, presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 10 Oct 2017 Status changed from active, no longer recruiting to completed.
- 30 Aug 2017 New trial record